Featured Content

Latest Press Releases

Jan 22, 2020 The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
Jan 21, 2020 FDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
Jan 13, 2020 Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs

See All Press Releases

Featured Videos

Going to Incredible Lengths: Buck Miller

For Us, It’s Personal

#RAREis: Francis’ Rare Disease Adoption Story in Song

Giving Back is Personal

Fact Sheets & Downloads

See All Fact Sheets

Logo Download

Download Horizon Logo | RGB Full Color (.jpg)
Download Horizon Logo | RGB Full Color (.png)
Download Horizon Logo | Charcoal Single Color (.jpg)
Download Horizon Logo | Charcoal Single Color (.png)

If you are looking for additional Horizon media assets, please contact corporatecommunications@horizontherapeutics.com

Media Inquiries

For U.S. media inquiries, contact:
Geoff Curtis
Senior Vice President, Corporate Affairs
media@horizontherapeutics.com
+1 (888) 506-2562

For EU media inquiries, contact:
Ray Gordon
Managing Director
ray@gordonmrm.ie
+353 (87) 2417373